In Vitro ADME Testing Services Market, 2019-2030 By Roots Analysis

BUCKLEY, Wash. - Jan. 14, 2021 - PRLog -- Roots Analysis has announced the addition of "In Vitro ADME Testing Services Market, 2019-2030" report to its list of offerings.

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with their pharmacokinetic profiles, ADME properties and inherent toxicity. ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates.

Key Market Insights

Nearly 100 players currently claim to provide in vitro ADME testing services

Nearly 60% of these companies are small and mid-sized firms. Further, close to 35% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes.

Nearly 80% of in vitro ADME testing service providers are based in the developed geographies

Within North America, the US has the maximum number of players, whereas, in Europe, most of the service providers are distributed across France, Germany, the UK, and Spain. On the other hand, there are companies that are using this approach for drug discovery operations, in emerging regions, such as Australia, India and China, as well.

Over 85% companies claim to offer assays for drug metabolism and elimination testing

Further, nearly 70% companies claim to have capabilities to conduct absorption and distribution related studies, respectively. It is worth mentioning that about 35% of players presently offer end-to-end drug discovery services.

Nearly 95% CROs have received operational approval and certification from the USFDA

In addition, companies have received necessary certifications from the EMA (50%), MHLW / PMDA (15%), ICH (13%), WHO (11%), MHRA (11%), followed by CFDA / MFDS / SFDA (9%) and TGA (4%).

Over 35 acquisitions have taken place amongst various stakeholders, between 2005-2018

The addition of capabilities (primarily related to drug metabolism and pharmacokinetics testing) emerged as the most important value drivers across all the acquisitions. Other key value drivers include geographical consolidation and geographical expansion.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html
You may also be interested in the following titles:

1.     In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (https://www.rootsanalysis.com/reports/view_document/in-si...), 2020-2030

2.     AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030

3.     Bioavailability Enhancement Technologies and Services Market, 2020-2030

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com